Brief: Paratek Pharmaceuticals Announces Initiation Of Phase 2B Study In Nontuberculous Mycobacterial Pulmonary Disease
16/06/2021 12:37
June 16 (Reuters) - Paratek Pharmaceuticals Inc PRTK.O :
* PARATEK PHARMACEUTICALS ANNOUNCES INITIATION OF PHASE 2B
STUDY
IN NONTUBERCULOUS MYCOBACTERIAL (NTM) PULMONARY DISEASE CAUSED
BY MYCOBACTERIUM ABSCESSUS COMPLEX (MABC) WITH NUZYRA®
(OMADACYCLINE)
Source text for Eikon: ID:nGNXgcNlj
Further company coverage: PRTK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Paratek Pharmaceuticals
See all newsNovo Holdings closes $462 mln acquisition of Paratek Pharmaceuticals
Brief: Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Responds to Demand Letters From 11 Stockholders Alleging 'Misleading', Incomplete Statements In Proxy Statement Filed On June 30
Brief: Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue Of $40.0 Million